Allergen Immunotherapy

What is allergy?

Allergies are caused by an overreaction of the body’s immune system to substances that in most cases would otherwise be harmless.
Common triggers of respiratory allergic disease include pollens, house dust mites, moulds and animal dander. Exposure can lead to a range of symptoms, including allergic rhinitis (inflammation of the upper airways), conjunctivitis (itchy, watery eyes), and allergic asthma (inflammation of the lower airways).

Approximately 50% of allergic rhinitis patients go undiagnosed and nearly 30% of patients on symptomatic treatment are not fully controlled.
In Europe, the regulation of therapies for allergic diseases largely takes place at Member State level.

EBE Allergen ImmunoTherapy (AIT) Task Force

EBE created in 2015 an AIT Task Force with the support of its 5 member companies active in the AIT sector.
This Task Force aims to unite industry experts within allergen immunotherapy and harmonise the regulatory framework in Europe.

The activities of the Task Force include:

  • Development of common industry standpoints on AIT to be used as a platform for external communication
  • Engagement with policy decision makers in the EU system to increase awareness of the necessity of stricter harmonisation across the EU

EBE signed the united action for allergy and asthma launched by the European Academy of Allergy and Clinical Immunology (EAACI).